Chemistry:DSP-6745

From HandWiki

DSP-6745 is a serotonergic agent which was under development for the treatment of psychotic disorders but was never marketed.[1][2][3] It is taken orally.[1]

The drug acts as a serotonin reuptake inhibitor (SRI) and as an antagonist of the serotonin 5-HT2A, 5-HT2C, and 5-HT7 receptors.[3] Its affinities (Ki) were 0.653 nM for the serotonin transporter (SERT), 0.331 nM for the serotonin 5-HT2A receptor, 1.34 nM for the serotonin 5-HT2C receptor, and 31.7 nM for the serotonin 5-HT7 receptor.[3] Conversely, its IC50 or Kb values were 0.753 nM at the SERT, 0.566 nM at the serotonin 5-HT2A receptor, 1.37 nM at the serotonin 5-HT2C receptor, and 2.12 nM at the serotonin 5-HT7 receptor.[3] It also shows lower affinity for a number of other receptors, such as the serotonin 5-HT2B receptor (Ki = 7.58 nM).[3] DSP-6745 produces antidepressant-like, anxiolytic-like, antipsychotic-like, and pro-cognitive effects in animals.[3]

The chemical synthesis of DSP-6745 has been described.[3]

DSP-6745 was first described in the scientific literature by 2024.[3] It was under development by Sumitomo Dainippon Pharma or Sumitomo Pharma.[1][2] The drug reached phase 1 clinical trials for psychotic disorders prior to the discontinuation of its development in November 2022.[1][2]

See also

References

  1. ↑ 1.0 1.1 1.2 1.3 "DSP 6745". 21 November 2022. https://adisinsight.springer.com/drugs/800048770. 
  2. ↑ 2.0 2.1 2.2 "Delving into the Latest Updates on DSP-6745 with Synapse". 16 May 2026. https://synapse.patsnap.com/drug/90544e931b614e6c9a4c310e70c85477. 
  3. ↑ 3.0 3.1 3.2 3.3 3.4 3.5 3.6 3.7 "DSP-6745, a novel 5-hydroxytryptamine modulator with rapid antidepressant, anxiolytic, antipsychotic and procognitive effects". Psychopharmacology (Berl) 241 (11): 2223–2239. November 2024. doi:10.1007/s00213-024-06629-2. PMID 38856765. 



Retrieved from "https://handwiki.org/wiki/index.php?title=Chemistry:DSP-6745&oldid=4583552"